RUNX1T1 and acute myeloid leukemia: Despite more than two decades of preclinical and translational research on AML1/ETO, there still remain a number of open questions that need to be addressed in order to introduce novel therapeutic approaches into the treatment of patients with t(8;21) positive AML.